The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gomon Yu.M.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Kolbin A.S.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
Saint Petersburg State University, Saint Petersburg, Russia

Lavrova V.A.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Neznanov N.G.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
Bechterev National Research Center of Psychiatry and Neurology, Saint Petersburg, Russia

Spiridonov T.R.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Sales of antipsychotics and anticonvulsants in the Russian Federation for the period 2019—2024

Authors:

Gomon Yu.M., Kolbin A.S., Lavrova V.A., Neznanov N.G., Spiridonov T.R.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2026;48(1): 134‑142

DOI: 10.17116/medtech202648011134

Read: 243 times

Buy for 300₽
Contact the author
Table of contents

SALES OF ANTIPSYCHOTICS AND ANTICONVULSANTS IN THE RUSSIAN FEDERATION FOR THE PERIOD 2019—2024
SALES OF ANTIPSYCHOTICS AND ANTICONVULSANTS IN THE RUSSIAN FEDERATION FOR THE PERIOD 2019—2024

To cite this article:

Gomon YuM, Kolbin AS, Lavrova VA, Neznanov NG, Spiridonov TR. Sales of antipsychotics and anticonvulsants in the Russian Federation for the period 2019—2024. Medical Technologies. Assessment and Choice. 2026;48(1):134‑142. (In Russ.)
https://doi.org/10.17116/medtech202648011134

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Search for risk factors for slowed intra-atrial conduction in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):111-116
Abstract:

OBJECTIVE

To assess the structure and volume of consumption of antipsychotics, anticonvulsants and gabapentinoids in patients with neurotic disorders in the Russian Federation for the period 2019—2024.

MATERIAL AND METHODS

Data on sales of ATC class N05A (antipsychotics), N03A (anticonvulsants), and N02BF (gabapentinoids) according to current Russian clinical guidelines used in patients with neurotic, stress-related and somatoform disorders (ICD code F40-F48) in the period 2019—2024 were downloaded from the IQVIA database. Consumption data were taken into account for each INN in each year of follow-up in accordance with the defined daily doses (DDDs). The indicator “number of DDDs/1000 inhabitants per day” was calculated.

RESULTS

In 2019—2024, sales of antipsychotics in retail segment of the Russian Federation increased by 2 times (from 28.1 million DDDs in 2019 to 58.5 million DDDs in 2024) mainly due to atypical antipsychotics (quetiapine, olanzapine, risperidone). Estimated consumption increased from 1.08 DDDs/1.000 inhabitants per day in 2019 to 1.78 DDDs/1.000 inhabitants per day in 2024. There was a significant increase in sales of gabapentinoids (from 29 million DDDs in 2019 to 191 million DDDs in 2024) primarily due to multiple increase in sales of gabapentin. Sales of anticonvulsants in retail network increased slightly (from 77.1 million DDDs in 2019 to 83.7 DDDs in 2024).

CONCLUSION

There are high risks of prescribing these classes of drugs off-label. Considering expansion of their prescriptions, it is necessary to conduct high-quality studies for assessing their effectiveness and safety, including patients with neurotic disorders.

Keywords:

defined daily doses
antiepileptic
gabapentinoids
antipsychotics
neurotic disorders
off-label
quetiapine
pregabalin

Authors:

Gomon Yu.M.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Kolbin A.S.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
Saint Petersburg State University, Saint Petersburg, Russia

Lavrova V.A.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Neznanov N.G.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
Bechterev National Research Center of Psychiatry and Neurology, Saint Petersburg, Russia

Spiridonov T.R.

Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

Received:

03.04.2025

Accepted:

16.07.2025

Close metadata

References:

  1. Hefner G, Wolff J, Toto S, Reißner P, Klimke A. Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. Journal of Neural Transmission (Vienna). 2022;129(11):1353-1365. https://doi.org/10.1007/s00702-022-02542-0
  2. Park SY, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis SH, et al. Antipsychotic Use Trends in Youth with Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. Journal of the American Academy of Child and Adolescent Psychiatry. 2016;55:456-468.e4.  https://doi.org/10.1016/j.jaac.2016.03.012
  3. Petrova NN, Semenova NV. Prescription of psychotropic drugs off label. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7):130-135. (In Russ.). https://doi.org/10.17116/jnevro2023123071130
  4. Rucker JJ, Iliff J, Nutt DJ. Psychiatry and the psychedelic drugs. Past, present and future. Neuropharmacology. 2018;142:200-218.  https://doi.org/10.1016/j.neuropharm.2017.12.040
  5. Chokhawala K, Stevens L. Antipsychotic Medications In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Accessed December 4, 2025. https://www-ncbi-nlm-nih-gov.ezproxy.library.sydney.edu.au/books/NBK519503/
  6. Højlund M, Andersen JH, Andersen K, Correll CU, Hallas J. Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses. Epidemiology and Psychiatric Sciences. 2021;30:e28.  https://doi.org/10.1017/S2045796021000159
  7. Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Coma Fusté A, et al. International trends in antipsychotic use: a study in 16 countries, 2005-2014. European Neuropsychopharmacology. 2017;27(10):1064-1076. https://doi.org/10.1016/j.euroneuro.2017.07.001
  8. Johansen ME, Maust DT. Update to Gabapentinoid Use in the United States, 2002-2021. Annals of Family Medicine. 2024;22(1):45-49.  https://doi.org/10.1370/afm.3052
  9. Paton C, Citrome L, Fernandez-Egea E, Rendora O, Barnes TRE. Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit. Therapeutic Advances in Psychopharmacology. 2022;12:20451253221110016. https://doi.org/10.1177/20451253221110016
  10. Pearl NZ, Babin CP, Catalano NT, Blake JC, Ahmadzadeh S, Shekoohi S, et al. Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations. Advances in Therapy. 2023;40(9):3626-3638. https://doi.org/10.1007/s12325-023-02586-y
  11. Carton L, Cottencin O, Lapeyre‐Mestre GPA, Geoffroy PA, Favre J, Simon N, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Current Pharmaceutical Design. 2015;21:3280-3297. https://doi.org/10.2174/1381612821666150619092903
  12. Costales B, Goodin AJ. Outpatient Off-Label Gabapentin Use for Psychiatric Indications among U.S. Adults, 2011-2016. Psychiatric Services. 2021;72(11):1246-1253. https://doi.org/10.1176/appi.ps.202000338
  13. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-150.  https://doi.org/10.1016/S2215-0366(21)00395-3
  14. Garakani A, Buono FD, Salehi M, Funaro MC, Klimowicz A, Sharma H, et al. Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatrica Scandinavica. 2024;149(4):295-312.  https://doi.org/10.1111/acps.13669
  15. Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Molecular Psychiatry. 2022;27(3):1339-1349. https://doi.org/10.1038/s41380-021-01386-6
  16. Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U, et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Frontiers in Psychiatry. 2019;10:228.  https://doi.org/10.3389/fpsyt.2019.00228
  17. Munkholm K, Ussing A, Brink M, Edemann-Callesen H, Canbolat SS, Christensen R, et al. Minor tranquillizers for short-term treatment of newly onset symptoms of anxiety and distress: a systematic review with network meta-analysis of randomized trials. European Archives of Psychiatry and Clinical Neuroscience. 2024;274(3):475-486.  https://doi.org/10.1007/s00406-023-01680-0
  18. Grabitz P, Saksone L, Schorr SG, Schwietering J, Bittlinger M, Kimmelman J. Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis. Society for Clinical Trials. 2024;21(4):418-429.  https://doi.org/10.1177/17407745231225470
  19. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-156.  https://doi.org/10.1007/s40265-020-01432-7
  20. McAnally H, Bonnet U, Kaye AD. Gabapentinoid Benefit and Risk Stratification: Mechanisms over Myth. Pain and Therapy. 2020;9(2):441-452.  https://doi.org/10.1007/s40122-020-00189-x
  21. Zhou L, Bhattacharjee S, Kwoh CK, Tighe PJ, Reisfield GM, Malone DC, et al. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study. Addiction. 2021;116(4):819-830.  https://doi.org/10.1111/add.15189
  22. de Moraes FCA, Sudo RYU, Souza MEC, Fernandes MR, Carneiro Dos Santos NP. The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients. BMC Cancer. 2024;24(1):712.  https://doi.org/10.1186/s12885-024-12481-6
  23. Liu Z, Zhang ML, Tang XR, Li XQ, Wang J, Li LL. Cardiotoxicity of current antipsychotics: Newer antipsychotics or adjunct therapy? World Journal of Psychiatry. 2022;12(8):1108-1111. https://doi.org/10.5498/wjp.v12.i8.1108
  24. Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, et al. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology. 2022;47(3):664-672.  https://doi.org/10.1038/s41386-021-01163-7
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.